Regeneron’s Otarmeni Becomes the Latest Gene Therapy Approved Via Priority Voucher

Regeneron Pharmaceuticals has achieved a major milestone in genetic medicine with the U.S. Food and Drug Administration’s approval of Otarmeni (lunsotogene parvec-cwha), the first gene therapy approved under the FDA Commissioner’s National Priority Voucher program. The April 23, 2026 approval also makes Otarmeni the first FDA-approved gene therapy for a genetic form of hearing loss.

A First-of-Its-Kind Gene Therapy for Genetic Hearing Loss

Otarmeni is designed to treat severe-to-profound and profound sensorineural hearing loss caused by confirmed mutations in both copies of the OTOF gene. The condition affects the production of otoferlin, a protein required for transmitting auditory signals from inner-ear hair cells to the auditory nerve.

Unlike conventional hearing devices, Otarmeni targets the underlying genetic cause of the disorder. The therapy uses a dual AAV1 vector system to deliver a functional copy of the human OTOF gene directly into the inner ear through intracochlear infusion.

The approval is therefore significant beyond the hearing-loss market: it represents a step toward using gene therapy to restore a neurosensory function rather than simply managing its symptoms.

Strong Clinical Results Supported the Approval

The FDA's accelerated approval was supported by results from Regeneron's pivotal CHORD trial. According to the company, 80% of evaluable participants achieved or surpassed the trial's primary hearing endpoint. With longer follow-up, 42% achieved hearing levels that included the ability to hear whispers and were considered within the normal range.

The FDA reported that among 20 patients evaluable for efficacy, 80% experienced improved hearing, an outcome that would not be expected from the natural history of the disease without intervention.

These results helped establish the potential of Otarmeni as more than a symptomatic treatment, particularly for children born with this rare genetic condition.

What Makes the Priority Voucher Important?

Otarmeni's approval is also notable because of the regulatory pathway used to review it.

The FDA's Commissioner's National Priority Voucher (CNPV) pilot program is designed to accelerate the review of products considered to have important national or public-health significance. Regeneron's application was reviewed through this program, and the FDA approved the therapy 61 days after the Biologics License Application (BLA) was filed.

The approval was the sixth approval under the CNPV pilot program and the first gene therapy approved through it. It was also tied for the fastest BLA approval in modern FDA history, according to the agency.

The development demonstrates how regulatory acceleration programs could become increasingly important for advanced therapies where rapid access may have a meaningful impact on patients with rare and severe diseases.

Otarmeni Also Earned a Priority Review Voucher

The regulatory significance continued after approval.

The FDA subsequently determined that Otarmeni met the criteria for a Rare Pediatric Disease Priority Review Voucher. The agency's Federal Register notice confirms that the voucher was issued to Regeneron because the product satisfied the statutory requirements for an approved rare pediatric disease product.

This creates an additional strategic asset for Regeneron. Priority review vouchers can provide qualifying sponsors with a faster FDA review pathway for a future eligible product, potentially reducing the time required to bring another important medicine to market.

The case therefore illustrates how regulatory incentives can influence pharmaceutical development beyond a single product's approval.

A New Direction for Gene Therapy

Otarmeni is particularly important because it is Regeneron's first approved genetic medicine. The company has positioned the product as an example of its expanding capabilities in genetic medicines and advanced therapeutic platforms.

The therapy also demonstrates the growing potential of AAV-based technologies. By delivering a functional gene directly to the inner ear, the treatment attempts to address the biological mechanism responsible for the patient's hearing impairment.

However, the approval does not mean gene therapy has solved genetic hearing loss broadly. Otarmeni is intended for a specific genetically confirmed patient population, meaning genetic testing and appropriate clinical evaluation remain essential for identifying eligible patients.

Safety and Long-Term Monitoring Remain Important

As with other advanced gene therapies, long-term durability and safety remain important considerations.

The FDA's accelerated approval means continued evidence will be required. Continued approval may depend on further assessment of the durability of hearing improvement, as well as verification of effects on speech development and quality of life.

Reported adverse effects included middle-ear infection, nausea, dizziness and procedural pain. The FDA also noted that healthcare providers should monitor patients for surgical complications associated with administration.

These requirements highlight an important reality for the gene-therapy sector: regulatory approval is increasingly becoming the beginning of long-term evidence generation rather than the end of clinical development.

Regeneron Plans Free U.S. Access

Another unusual feature of the Otarmeni launch is Regeneron's plan to provide the therapy at no cost to eligible patients in the United States. The company announced the policy alongside the FDA approval.

For a one-time gene therapy, affordability can be a major barrier to adoption. Providing the treatment free to eligible U.S. patients could therefore create a different model for commercializing high-impact genetic medicines.

It may also influence broader discussions around how healthcare systems should pay for one-time treatments that potentially deliver long-lasting benefits.

What This Means for the Gene Therapy Market

Otarmeni's approval could have implications well beyond rare genetic hearing loss.

First, it provides another demonstration that gene therapy can move from experimental development to treatment of a specific human genetic defect. Second, its approval through the National Priority Voucher program could encourage companies developing other advanced therapies to pursue regulatory pathways that prioritize products with significant public-health importance.

The case also reinforces the importance of genetic diagnosis. As more therapies are designed around specific mutations, identifying the molecular cause of a disease becomes increasingly important for determining treatment eligibility.

For pharmaceutical companies, this creates opportunities across gene delivery, genetic testing, vector manufacturing, specialized surgical delivery and long-term patient monitoring.

Conclusion

Regeneron's Otarmeni marks several milestones at once: it is the first FDA-approved gene therapy for genetic hearing loss, the first gene therapy approved through the Commissioner's National Priority Voucher program, and Regeneron's first approved genetic medicine.

Its approval demonstrates how advances in gene delivery, clinical research and accelerated regulatory pathways are converging to bring highly targeted therapies to patients with rare diseases.

The bigger question now is whether Otarmeni will become a model for the next generation of genetic medicines—where correcting the underlying biological cause of disease, rather than managing its symptoms, becomes an increasingly realistic therapeutic strategy.